These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 7491833)

  • 21. Should transdermal rather than oral estrogens be used in menopausal hormone therapy? A review.
    Fournier A
    Menopause Int; 2010 Mar; 16(1):23-32. PubMed ID: 20424283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins.
    Vrablik M; Fait T; Kovar J; Poledne R; Ceska R
    Metabolism; 2008 Aug; 57(8):1088-92. PubMed ID: 18640386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone replacement therapy and cardiovascular disease.
    McPherson R; Tardif JC; Jolly E
    Can J Cardiol; 2001 Nov; 17 Suppl D():32D-37D. PubMed ID: 11726994
    [No Abstract]   [Full Text] [Related]  

  • 24. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors.
    Wilcox JG; Hatch IE; Gentzschein E; Stanczyk FZ; Lobo RA
    Fertil Steril; 1997 Feb; 67(2):273-7. PubMed ID: 9022602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Biological and practical aspects of hormone replacement therapy: an approach to cardiovascular disease prevention in postmenopausal women].
    da Silva PM
    Rev Port Cardiol; 1999 Nov; 18(11):1047-55. PubMed ID: 10608165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of continuation of postmenopausal hormone replacement therapy: transdermal versus oral estrogen.
    Ettinger B; Pressman A; Bradley C
    Menopause; 1998; 5(3):152-6. PubMed ID: 9774760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
    Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of hormone replacement therapy on hemostatic variables in post-menopausal women.
    Al-Farra HM; Al-Fahoum SK; Tabbaa MA
    Saudi Med J; 2005 Dec; 26(12):1930-5. PubMed ID: 16380775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasoactive biomarkers and oxidative stress in healthy recently postmenopausal women treated with hormone replacement therapy.
    Maffei S; Mercuri A; Prontera C; Zucchelli GC; Vassalle C
    Climacteric; 2006 Dec; 9(6):452-8. PubMed ID: 17085378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of oral and transdermal short-term estrogen therapy in postmenopausal women with metabolic syndrome.
    Chu MC; Cosper P; Nakhuda GS; Lobo RA
    Fertil Steril; 2006 Dec; 86(6):1669-75. PubMed ID: 17074346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women.
    Maffei S; Del Ry S; Prontera C; Clerico A
    Clin Sci (Lond); 2001 Nov; 101(5):447-53. PubMed ID: 11672449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Do the cardiovascular disease risks and benefits of oral versus transdermal estrogen therapy differ between perimenopausal and postmenopausal women?
    Clarkson TB; Karas RH
    Menopause; 2007; 14(6):963-7. PubMed ID: 17909452
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral but not transdermal estrogen replacement therapy reduced level of tissue factor pathway inhibitor: cross-over designed study.
    Fait T; Vrablik M; Cibula D; Masata J; Hill M; Trnkova B
    Neuro Endocrinol Lett; 2006 Oct; 27(5):665-8. PubMed ID: 17159824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Hormone replacement therapy and cardiovascular risk].
    Maffei S; De Caterina R
    G Ital Cardiol; 1996 Aug; 26(8):899-940. PubMed ID: 9005173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
    Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
    Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Oral contraception and menopausal hormone replacement: effects on hemostasis and risk of venous thromboembolism].
    Bounameaux H; de Moerloose P; Campana A
    Schweiz Med Wochenschr; 1996 Oct; 126(41):1756-63. PubMed ID: 8966508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of hormone replacement therapy with femoston on hemostasis in peri- and postmenopausal women.
    Repina MA; Korzo TM; Zinina TA
    Med Sci Monit; 2002 Sep; 8(9):PI78-84. PubMed ID: 12218956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement.
    Kalantaridou SN; Naka KK; Bechlioulis A; Makrigiannakis A; Michalis L; Chrousos GP
    Trends Endocrinol Metab; 2006 Apr; 17(3):101-9. PubMed ID: 16515863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hormone replacement therapy and cardiovascular risk in postmenopausal women].
    Kovacev-Zavisić B; Icin T; Kovacev N
    Med Pregl; 2009; 62 Suppl 3():85-90. PubMed ID: 19702123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemostatic factors and risk of cardiovascular disease in women. An overview.
    Meilahn EN
    Arch Pathol Lab Med; 1992 Dec; 116(12):1313-7. PubMed ID: 1456877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.